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At-a-Glance Commentary 
Results from multiple clinical trials have demonstrated that fixed combinations of long-acting β-
adrenergic agonists (LABA) and long-acting muscarinic antagonists (LAMA) are significantly 
superior to their monocomponents and to the combination LABA and an inhaled corticosteroid 
in decreasing the frequency of exacerbations in patients with chronic obstructive pulmonary 
disease. At present, the mechanism(s) underlying this clinical benefit are not fully understood. 
This review considers potential mechanisms whereby LABA/LAMA combinations might exert 
additive or synergistic effects that lead to a decrease in exacerbations. Mechanisms considered 
include effects on lung hyperinflation and mechanical stress, inflammation, excessive mucus 
production with impaired mucociliary clearance, and symptom severity and variability. 
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Abstract 
Decreasing the frequency and severity of exacerbations is one of the main goals of treatment 
for patients with chronic obstructive pulmonary disease (COPD). Several studies have 
documented that long-acting bronchodilators (LABDs) can reduce exacerbation rate and/or 
severity, and others have shown that combinations of long-acting β2-adrenergic agonists 
(LABAs) and long-acting muscarinic antagonists (LAMAs) provide greater reductions in 
exacerbation frequency than either their monocomponents or LABA/inhaled corticosteroids 
(LABA/ICS) combinations in patients at low and high risk for these events. In this review, small 
groups of experts critically evaluated mechanisms potentially responsible for the increased 
benefit of LABA/LAMA combinations over single LABDs or LABA/ICS in decreasing exacerbation. 
These included effects on lung hyperinflation and mechanical stress, inflammation, excessive 
mucus production with impaired mucociliary clearance, and symptom severity. The data 
assembled and analyzed by each group were reviewed by all authors and combined into this 
manuscript. Available clinical results support the possibility that effects of LABA/LAMA 
combinations on hyperinflation, mucociliary clearance, and symptom severity may all 
contribute to decreasing exacerbations. While preclinical studies suggest LABAs and LAMAs 
have anti-inflammatory effects, such effects have not been demonstrated yet in patients with 
COPD. 
 
Word count: 188 
 
Key words: hyperinflation, inflammation, inhaled corticosteroid, mucus  
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Introduction 
Exacerbations are cardinal events in the lives of patients with COPD(1). Exacerbations 
accelerate the decline in pulmonary function (2), increase the risk for acute cardiovascular 
events (3), decrease health status (4, 5), impair activities of daily living (6, 7), and increase the 
risk for future hospital admissions for COPD exacerbations (8) and mortality (9). Accordingly, 
the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendations for the 
treatment of COPD patients have identified reducing the risk for exacerbations as one of the 
major goals of management for these individuals (10). 
 
There are various risk factors for exacerbations including older age (11), presence and severity 
of symptoms (cough, sputum, and dyspnea) (4, 12), poor health status (4, 13), more severe 
airflow limitation (14), presence of hyperinflation (15), persistent pulmonary and systemic 
inflammation (16, 17), airway bacterial colonization (18), cardiovascular comorbidities (19, 20), 
and gastroesophageal reflux disease (21). However, the most important indicator of future 
exacerbation risk is the past exacerbation history (14). 
 
Long-acting bronchodilators (LABDs) are central to the management of patients with COPD, and 
clinical trial results have repeatedly demonstrated the efficacy of these agents in decreasing the 
frequency and severity of exacerbations together with improvement in other clinically relevant 
endpoints (22-24). Inhaled corticosteroids (ICS) in combination with a LABA have also 
demonstrated efficacy in decreasing exacerbations and improving COPD symptoms (25). 
Recently, the two classes of LABDs, long-acting β2-adrenergic agonists (LABAs) and long-acting 
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muscarinic antagonists (LAMAs), have been combined in single inhalers in an effort to improve 
lung function, symptoms, and clinical outcomes, including risk for exacerbations, in COPD (26, 
27, 28). The combination of indacaterol and glycopyrronium has been shown to provide 
reductions in exacerbations greater than those achieved with a single long-acting 
bronchodilator (29) and to have significant superiority over the LABA/ICS combination in 
decreasing exacerbation risk (24, 30). Results from the 52-week FLAME study comparing 
indacaterol/glycopyrronium once daily vs the LABA/ICS combination of salmeterol/fluticasone 
showed that the LABA/LAMA combination was significantly superior to LABA/ICS in increasing 
the times to and decreasing the rates of all and moderate or severe exacerbations, and 
increasing the time to severe exacerbations (mild = worsening of symptoms for >2 consecutive 
days but not leading to treatment with systemic glucocorticoids or antibiotics; moderate = 
leading to treatment with systemic glucocorticoids, antibiotics, or both; severe = leading to 
hospital admission or a visit to the emergency department that lasted >24 hours in addition to 
treatment with systemic glucocorticoids, antibiotics, or both [31]) (29). The importance of 
accurate exacerbation detection was highlighted in this study that used electronic diaries to 
detect and flag exacerbations; this resulted to higher rates of reported exacerbations vs most 
previous studies, but the authors emphasized that this was unlikely to bias treatment 
comparisons. This view is supported by the fact that results for mild exacerbations (those most 
likely to be increased with the reporting method used) were matched by those for moderate or 
severe exacerbations (29). Other results have suggested that the superiority of 
indacaterol/glycopyrronium over LABA/ICS may not extend to all other LABA/LAMA 
combinations. Results from a 24-week comparison of aclidinium/formoterol vs 
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salmeterol/fluticasone in 933 patients with COPD indicated no significant between-treatment 
difference for exacerbation frequency (32).  
 
The reason(s) for the superiority of LABA/LAMA over single LABDs and LABA/ICS in reducing 
exacerbation is not clear. Clinical studies have highlighted the additive effect of LABAs and 
LAMAs when they are administered together (33), and some preclinical studies provide some 
implications for potential synergistic effects (34, 35). Inhibition of M2 receptors enhances the 
actions of norepinephrine at β2 receptors by interacting with adenylyl cyclase to raise 
intracellular cyclic adenosine monophosphate (cAMP) levels in airway smooth muscle cells and 
thus relax airway smooth muscle (35). Interestingly, this interaction only lasts for a few hours, 
which has led to speculation about the potential improvements in efficacy when a LABA and 
LAMA are administered together (36).  
 
The aim of this narrative review is to summarize the evidence regarding the possible 
mechanisms underlying the ability of LABDs, and especially dual bronchodilation, to decrease 
the frequency of COPD exacerbations. The main mechanisms related to the reduction of 
exacerbations by LABDs explored in this review include the decrease in hyperinflation and 
mechanical stress, the modulation of mucus production and mucociliary clearance, the 
improvement of symptoms fluctuation and severity, and some potential direct and indirect 
anti-inflammatory properties (Figure 1).  
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Methodology used in the development of this review 
The content of the manuscript was developed in the following way: 1) Small working groups 
comprised of three to four of the authors searched, reviewed, and interpreted the relevant 
literature for a given section of the manuscript (eg, hyperinflation) and developed the initial 
draft; 2) Sections were assembled using editorial support; 3) All portions of the manuscript 
were reviewed by each of the authors; and 4) The manuscript was revised and submitted. All 
authors agree on the content of the manuscript.  
 
Improvement in static and dynamic hyperinflation 
Hyperinflation is characterized by an increased volume of air remaining in the lungs at the end 
of tidal expiration, leading to increased resting functional residual capacity (FRC) (37). 
Hyperinflation can either be static or dynamic. Static hyperinflation is present during tidal 
breathing and leads to changes in shape of the thorax (barrel-shaped chest wall), while dynamic 
hyperinflation results from rapid breathing, hyperventilation, and exercise. Most patients with 
COPD have some degree of hyperinflation (37), and there is a significant relationship between 
hyperinflation and dyspnea (38). Hyperinflation is also a better predictor of exercise capacity 
than FEV1 in patients with COPD (39). Hyperinflation adversely affects cardiovascular and 
diaphragmatic function in patients with COPD, decreasing ventricular preload and venous 
return at rest and during exercise and increasing left ventricular afterload (40, 41). 
Hyperinflation is also associated with increased mortality in patients with COPD (42). 
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Exacerbations are characterized by the occurrence or worsening of lung hyperinflation. Airway 
resistance is abruptly increased during exacerbations as a result of bronchospasm, mucosal 
edema, and decreased fluidity of sputum. These changes worsen expiratory flow limitation, 
prolong the time constant for lung emptying, and increase end expiratory lung volume (EELV). 
Patients also tend to adopt a rapid shallow breathing pattern during exacerbations. This further 
limits the time available for lung emptying and exacerbates dynamic hyperinflation (Figure 2A) 
(43, 44, 45). Recovery of dyspnea following acute exacerbations is associated with reduction in 
lung hyperinflation and increased expiratory flow rates (Figure 2B) (43). A mechanistic 
relationship between the reduction of hyperinflation and risk for exacerbations is supported by 
the decreased risk for exacerbations following lung volume reduction surgery (LVRS) (46). 
However, the changes in static lung volumes after LVRS did not predict reduction in 
exacerbation frequency (46), suggesting that other factors may contribute to this observation. 
 
Administration of LABA/LAMA decreases hyperinflation (47). LAMAs reduce cholinergic tone 
resulting in improved airway conductance (48), whereas LABAs relax airway smooth muscle, 
improve small airway patency, and enhance lung deflation, as reflected by a reduction in end 
expiratory lung volume (ie, dynamic FRC) (49). Respiration at a lower FRC decreases the work of 
breathing while placing the respiratory muscles in a more efficient arrangement for pressure 
generation (50). Decreased work of breathing and better ventilatory pump performance in turn 
result in improved exercise tolerance and a reduction in dyspnea (15, 49). Results from clinical 
trials have demonstrated that the combination of a LABA and a LAMA is significantly superior to 
a single bronchodilator and to a LABA plus ICS in improving spirometry measures related to 
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hyperinflation. A comparison of indacaterol plus glycopyrronium vs indacaterol alone showed 
that the combination was significantly superior to monotherapy in increasing inspiratory 
capacity (IC) (51). A study of 46 patients with COPD showed that the combination of indacaterol 
and tiotropium was significantly superior to salmeterol and fluticasone in increasing IC (+298.9 
vs 92.6 mL, P=0.043), but not FRC (-35.0 vs -23.3 mL, P=0.199) (52). The combination of 
formoterol and tiotropium has also been shown to be significantly superior to formoterol alone 
(P=0.027) in reducing EELV in a study of 33 patients with COPD (53). Indacaterol plus tiotropium 
has also been shown to be significantly superior to tiotropium monotherapy for improving IC 
(P<0.05 at all time points evaluated) in two studies that included a total of 2,276 patients with 
COPD (54). 
 
Hyperinflation is partly reversible with administration of bronchodilators, resulting in symptom 
improvement, most notably reduced dyspnea (55, 56). Decreasing the work of breathing in 
stable COPD via appropriate long-acting bronchodilators (LABD) treatment may thus lead to a 
greater difference between “steady state” and the threshold work of breathing that results in 
reporting of an exacerbation. Deflation of hyperinflated lungs with LABDs brings the thoracic 
cage into a more favorable position with improved diaphragmatic function and prolonged time 
to respiratory muscle fatigue (57). Hyperinflation may also result in alveolar stress and release 
of inflammatory cytokines. This potential inflammatory effect might also be reduced by 
administration of effective long-acting bronchodilation (58). The improvement in lung 
mechanics, combined with the reduction in dyspnea and the potential reduction of mechanical 
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stress in the lungs, represents the main plausible mechanisms for the potential reduction of 
exacerbations through the reduction of lung hyperinflation by dual bronchodilation. 
 
Reduction of mucus hypersecretion and improvement of mucociliary clearance 
Chronic cough and sputum production are associated with decline in FEV1 (59), increased risk 
for pulmonary infections (60), and elevated frequencies of exacerbations and hospitalizations 
(12). Overproduction and hypersecretion of mucus by airway epithelial goblet cells and by 
submucosal gland cells and decreased elimination of mucus are the primary mechanisms 
responsible for excessive mucus levels in COPD. A decreased number of ciliated cells lead to 
prolonged clearance times and airway mucus accumulation, and decreased mucociliary 
clearance is correlated with increased frequency of exacerbations in patients with COPD (61). 
Mucus accumulation in COPD patients has adverse effects on several important outcomes, such 
as lung function, health-related quality of life, exacerbations, hospitalizations, and mortality. 
Mucus plugging of small airways increases with COPD severity and is associated with decreased 
survival (62).  
 
Impact of anticholinergic therapy on mucus secretion  
Acetylcholine (ACh) induces mucus secretion predominantly via M3 receptors expressed on 
submucosal glands; and electrolytes and water secretion are regulated by muscarinic M1 and 
M3 receptors. It has also been shown that airway epithelial cells differentiate into goblet cells 
that produce mucus in response to ACh (63). 
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Results from experimental models have demonstrated that LAMAs decrease mucus production 
(64) and COPD patients treated with tiotropium have reported a subjective decrease in sputum 
production (65). MUC5AC is the predominant mucin gene expressed in human airway epithelial 
cells (66). The muscarinic agonist carbachol upregulates MUC5AC expression in these cells by 
activation of muscarinic receptors and transactivation of epidermal growth factor receptors 
(EGFR). Aclidinium has been shown to decrease this effect in vitro (67). Treatment with 
tiotropium has also been demonstrated to improve mucociliary clearance, as reflected by 
reduced nasal clearance time, in patients with COPD (68). 
 
Impact of β2 adrenoceptor agonist on mucociliary clearance 
There is evidence of impaired mucociliary clearance in patients with COPD and this may be 
associated with depressed ciliary beating (69). Mucociliary clearance efficiency depends on the 
capacity of apical plasma membrane ion channels to maintain airway hydration, ciliary beating, 
and appropriate rates of mucin secretion (70). LABD treatment has been shown to improve 
mucociliary clearance in patients with COPD. In one study, 24 patients with mild-to-moderate 
COPD receiving formoterol were assessed with a radioaerosol technique to determine effects of 
treatment on mucus clearance. Results indicated that a single dose of formoterol significantly 
enhanced radioaerosol clearance (71). Treatment with salmeterol also has been shown to 
increase mucociliary clearance in patients with COPD (72). 
 
Cough and sputum production (mucus in large airways) are related to exacerbations and the 
frequent exacerbator phenotype. There is good evidence from experimental models that 
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LAMAs decrease mucus production via blockade of ACh-induced EGFR activation. LABA 
exposure has been shown to increase ciliary beating in vitro, and there is some evidence that 
LABAs (but not LAMAs) increase mucociliary clearance in peripheral airways of COPD patients. 
However, there are no clinical data showing a relationship between decreased mucus 
hypersecretion and effects of LABDs on exacerbations and this represents a potential target for 
future studies.  
 
Symptom severity 
Symptoms per se are relevant in the natural history of COPD as demonstrated by results from 
the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) 
cohort, which suggested that the presence of symptoms is associated with increased future 
risk, as GOLD groups B and C carry equally poor clinical outcomes though for different reasons 
(73). GOLD subgroup B, characterized by more severe dyspnea, had significantly poorer survival 
than group C, in spite of higher FEV1 in a study of the general population in Copenhagen (74). 
This subgroup of patients warrants special attention, as the poor prognosis could be caused by 
cardiovascular disease or cancer, requiring additional assessment and treatment. Analysis of 
patients included in the Lung Health Study showed that the combination of cough and phlegm, 
but not either symptom alone, was associated with increased mortality risk over 12.5 years of 
follow-up (75). Higher overall symptom severity as measured by Chronic Obstructive Pulmonary 
Disease Assessment Test (CAT) scores is associated with increased risk for exacerbations (76). 
Dyspnea grade is also closely linked to risk for exacerbations (20), and severity of dyspnea is a 
significant predictor of mortality in patients with COPD (77). LABA/LAMA combinations have 
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been repeatedly shown to decrease symptom severity in patients with COPD; in the majority of 
studies, these reductions have been demonstrated to be significantly greater than those 
achieved with individual agents (78-80). However, it is not clear how improvement in symptoms 
with LABDs decreases the risk for exacerbations. 
 
Symptom variability and exacerbations 
Several studies have described fluctuations of COPD symptoms over the day, with morning 
considered the time when symptoms are more severe, whereas symptom severity has also 
been reported to vary over the course of weeks and months in patients with COPD (81). The 
COPD and Seretide: a Multi-Center Intervention and Characterization (COSMIC) Study evaluated 
the symptom diary cards of COPD patients and assessed symptom progression during the days 
prior to and after exacerbations (82). The perception of cough, sputum, dyspnea, and nocturnal 
awakenings steadily increased beginning 2 weeks prior to an exacerbation. Symptom variability 
did not change prior to the first and second moderate exacerbations; however, variability was 
substantial in the days before a hospital admission. Results from a second study suggested that 
patients who had 2 or more exacerbations in the previous year were more likely to experience 
variability in breathlessness over the course of a week (81). Donaldson et al. evaluated daily 
peak expiratory flow (PEF) variability using detrended fluctuation analysis (DFA) and showed 
that it is associated with exacerbation frequency in patients with COPD (83). In an additional 
analysis of PEF data from a double-blind study of tiotropium, the authors were able to show 
that PEF variability measured by DFA was responsive to treatment, ie it was lower in patients 
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receiving tiotropium compared to placebo, and may therefore serve as a surrogate marker of 
exacerbation frequency (83).  
 
LABD, symptom severity, and exacerbations 
In a pooled analysis of 23 studies of LABDs, the improvement in lung function, as expressed by 
improvement in trough FEV1, was associated with significant improvements in patient-reported 
outcomes, including quality of life and dyspnea, and in exacerbations (84). Results from 
additional studies have demonstrated strong correlations between severity of dyspnea and 
hyperinflation in patients with COPD (Figure 3A) (85-87); and decreased dyspnea following 
LABD treatment is correlated with improvement in measures associated with hyperinflation, 
such as inspiratory capacity (IC) and tidal volume (Figure 3B) (88, 89).  
 
The stabilization of the airway by effective long-acting bronchodilation may lead to a reduction 
of day-to-day variability of symptoms and this may lead to a reduction in the increased bursts 
of symptoms that may be reported as exacerbations. In Figure 4, we provide a schematic 
representation of potential mechanisms of symptom improvement at stable state and during 
the course of an exacerbation by treatment interventions. Dual bronchodilation may effectively 
lower both the baseline symptoms and the magnitude of symptoms during the exacerbation 
(Figure 4C). 
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In summary, symptoms contribute to the risk for exacerbations. The more effective 
improvement in symptoms by LABA/LAMA combinations compared to monocomponents and 
LABA/ICS may contribute to the decrease of exacerbations at the patient level.  
 
Anti-inflammatory properties of long-acting bronchodilators  
Results from multiple in vitro studies as well as those from experimental models of pulmonary 
disease have demonstrated anti-inflammatory effects of LABAs and LAMAs as well as additive 
effects of agents from these two classes. In contrast, limited data available from patients with 
COPD have not indicated significant anti-inflammatory effects of LABDs and it should be 
emphasized that the relationships between such findings and effects of LABD treatment on 
exacerbations in patients with COPD have not been established. 
 
Modulation of inflammation by β2 adrenoceptors and muscarinic receptors  
Both β2 adrenoceptors and muscarinic receptors may modulate inflammation. β2 
adrenoceptors are located not only on bronchial smooth muscle cells, epithelial cells, and 
pneumocytes, but also on multiple types of inflammatory cells (90). Stimulation of β2-
adrenergic receptors is believed to exert largely inhibitory effects on cells of the immune 
system by increasing levels of cAMP and protein kinase A (91). Activation of β2 adrenoceptors 
may also contribute to regulation of fluid transport (92) and may be important in the 
pathogenesis and/or resolution of acute lung injury.  
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M3 receptors are predominantly expressed in peripheral airways. Epithelial cells may release 
acetylcholine (ACh) in response to inflammatory stimuli, such as tumor necrosis factor (TNF)-α, 
contributing to locally regulated inflammation. In addition, inflammatory cells express 
muscarinic receptors, and anti-inflammatory effects of tiotropium may result from blockade of 
M3 receptors located on inflammatory cells (93). All five muscarinic cholinergic receptor 
subtypes (M1-M5) are expressed by dendritic cells, macrophages, T-cells, and B-cells (90, 94), 
and activation of M1 and M3 receptors may play an important role in the immune-responsivity 
of lymphocytes (95). 
 
Direct anti-inflammatory effects of LABDs 
Results from in vitro and in vivo experimental studies have demonstrated anti-inflammatory 
effects of LABDs (93, 94, 96, 97). Tiotropium reduces lipopolysaccharide-induced increases in 
neutrophils in a guinea pig model of COPD (96) and decreases TNF-α-mediated chemotaxis and 
reactive oxygen species release by alveolar macrophages isolated from patients with COPD (98). 
Tiotropium also attenuates the transforming growth factor (TGF)-β1-mediated neutrophilic 
inflammation in induced sputum of patients with COPD and combined administration with 
olodaterol augments this effect (Figure 5) (99).  
 
The combination of tiotropium and formoterol decreases human leukocyte antigen-antigen D–
related (HLA-DR) expression on lymphocytes as well activated CD4+ CD25+ cells in sputum from 
patients with COPD (100). LABD treatment may also decrease oxidative stress (101). Tiotropium 
has also been shown to decrease the replication of respiratory syncytial virus (RSV) in epithelial 
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cells and may reduce production of inflammatory cytokines, suggesting a potential anti-
inflammatory role on viral infections (102). It has also been shown that exposure to the 
combination of indacaterol and glycopyrronium resulted in greater decreases of interleukin (IL)-
1β-stimulated IL-8 production by fibroblasts and IL-1β-stimulated IL-6 production from airway 
smooth muscle cells isolated from patients with COPD than either drug alone (103). 
 
Activation of β2 adrenoceptors inhibits inflammatory responses by neutrophils and 
mononuclear cells in vitro and in mouse models of lung inflammation in vivo (104). 
Pretreatment with inhaled salmeterol inhibits lipopolysaccharide-induced neutrophil influx, 
neutrophil degranulation, TNF-α release, and HLA-DR expression in healthy subjects (105). 
 
Potential indirect anti-inflammatory effect of LABD 
The bronchial epithelium stretches and relaxes during the normal respiratory cycle, and both in 
vitro and ex vivo studies have demonstrated a marked effect of stretch on bronchial epithelial 
cell function, including production and release of inflammatory molecules (eg, IL-8 and TGF-β) 
(106). Mechanical stretch is also associated with increased mucus production by the airway 
epithelium (107). While data are not available for patients with COPD, the relation between 
mechanical factors and inflammation is supported by results from studies of patients with 
asthma, where compressive mechanical forces that arise during bronchoconstriction can induce 
airway remodeling without additional inflammation (108).  
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Clinical studies 
In contrast to the above-mentioned pleiotropic anti-inflammatory effects of LABD in vitro, most 
clinical study results have not provided strong support for anti-inflammatory effects of LAMAs 
or LABAs. Results from one study of patients treated with tiotropium indicated no significant 
effects of this intervention on airway and systemic inflammation, including sputum IL-8 and 
serum C-reactive protein (CRP) and IL-6 (109). Similarly, administration of salmeterol had no 
significant effects on numbers of inflammatory cells in sputum samples or bronchial biopsies in 
patients with COPD (110). Future trials will need to explore whether anti-inflammatory effects 
of LABDs observed in vitro can be demonstrated in patients with COPD. 
 
Potential differences in mechanisms underlying effects of LABD according to different types 
of exacerbations 
At present, there is limited information about the benefits of LABDs in preventing different 
types of exacerbations or the influence of specific comorbidities on the efficacy of LABD 
treatment. Blood eosinophil counts have been proposed as a marker to define exacerbations 
that might typically need corticosteroid treatment. Bafadhel et al. evaluated subjects at 
presentation to hospital with an exacerbation of COPD and stratified them into eosinophilic 
exacerbations if the peripheral blood eosinophil count on admission was ≥200 cells/μL and/or 
≥2% of the total leukocyte count; the observed detrimental effects of steroids in the group with 
low eosinophils suggested that eosinophils can be used for stratification of exacerbations (111). 
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The hypothesis that currently arises is whether the blood eosinophil count could be a marker 
that identifies patients in whom a certain treatment has greater efficiency in preventing 
exacerbations. Results from Investigating New Standards for Prophylaxis in Reducing 
Exacerbations (INSPIRE) study showed differences in treatment requirements for residual 
exacerbations in patients randomized to LABA/ICS vs LAMA alone (112). Over 2 years, the 
estimated overall rates of exacerbations did not differ between an ICS/LABA and a LAMA. 
However, exacerbations requiring antibiotics occurred more frequently in patients treated with 
LABA/ICS vs LAMA, while those requiring oral corticosteroids were significantly more common 
in patients treated with a LAMA vs those who received LABA/ICS (112).  
 
This suggests potential differentiation in the mechanisms underlying exacerbation prevention 
between these two treatments. Post hoc analyses of studies comparing LABA/ICS and LABA 
have suggested that the presence of increased eosinophil counts is associated with better 
response to LABA/ICS (113, 114). In a prospective analysis of blood eosinophils the FLAME 
study, the superiority of LABA/LAMA combination of indacaterol/glycopyrronium vs ICS/LABA in 
the reduction of the rate of COPD exacerbations was independent of the baseline blood 
eosinophil count (24). Therefore, we still need to clearly define the role of biomarkers before 
establishing a therapeutic strategy that properly identifies patients who may benefit from this 
diagnostic approach. 
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LABA/LAMA vs triple combination therapy 
While clinical trial results have demonstrated greater efficacy of LABA/LAMA combinations in 
decreasing the frequency of exacerbations, improving pulmonary function, and reducing 
symptom severity vs monocomponents and LABA/ICS, there is much less information about the 
efficacy of LABA/LAMA vs triple therapy (LABA/LAMA/ICS). Triple therapy has been shown to be 
significantly superior to LABA/ICS and LAMA monotherapy for improving pulmonary function 
and symptoms (115, 116). Results from the OPTIMAL study indicated no significant difference 
between tiotropium plus salmeterol and fluticasone vs tiotropium and salmeterol for the 
proportion of COPD patients experiencing exacerbations over 1 year of treatment (117). Triple 
therapy has been compared with LABA/ICS in TRILOGY, a randomized, parallel group, double-
blind, active-controlled study in which 1,368 patients received either beclomethasone, 
formoterol, and glycopyrronium or beclometasone and formoterol. Adjusted annual moderate-
to-severe exacerbation frequencies were 0.41 for triple therapy and 0.53 for beclomethasone 
and formoterol, corresponding to a 23% reduction in exacerbations with triple therapy vs 
LABA/ICS (118). Other recent results have shown that the combination of umeclidinium, 
vilanterol, and fluticasone showed a reduction in the annual rate of moderate/severe 
exacerbations over 52 weeks of treatment compared to budesonide/formoterol (119). The 
ongoing IMPACT study, which began in 2014 and is expected to report out in 2017, compares 
the effects of umeclidinium, vilanterol, and fluticasone vs fluticasone plus vilanterol and 
umeclidinium plus vilanterol in reducing the rate of exacerbations (120). The ongoing TRIBUTE 
trial also compares LABA/LAMA (indacaterol/glycopyrronium) vs triple therapy 
(beclomethasone/formoterol/glycopyrronium) and is also expected to report out in 2017 (121). 
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These two studies should provide information on the clinically relevant question of the 
potential benefit of triple therapy vs LABA/LAMA in the reduction of exacerbations in COPD. 
 
Conclusions 
The rationale for LABA/LAMA treatment in patients with COPD is well established and includes 
complementary additive effects on airflow obstruction. LABA/LAMA combinations have been 
shown to be more effective than single bronchodilators or the combination of LABA/ICS in 
decreasing COPD exacerbations, and here we have discussed several mechanisms by which this 
could occur. LABDs decrease hyperinflation and symptom severity, improve sputum clearance 
by reducing mucus hypersecretion and increasing mucociliary clearance, and improve 
symptoms and reduce symptom variability by “stabilizing” the airways in patients with COPD. 
The potential anti-inflammatory actions of LABDs demonstrated in vitro and in experimental 
models have not been confirmed in patients with COPD. Future studies focus on the correlation 
of patient-level results for each of these actions, and effects of LABD treatment on risk for 
exacerbations may provide insights regarding which actions of single agents play significant 
roles in reduction of exacerbations. This may explain the overall improvement in exacerbation 
reduction by dual bronchodilation. 
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Figure Legends 
Figure 1. Mechanisms by which LABA/LAMA may decrease the frequency of exacerbations 
 *Anti-inflammatory mechanisms have been demonstrated in vitro and in animal 
models, but have not been demonstrated yet in patients with COPD 
 
Figure 2. A. Schematic of mechanical effects of COPD exacerbation. Representative 
pressure-volume plots during stable COPD and during an exacerbation. During 
exacerbation, worsening expiratory flow limitation results in dynamic 
hyperinflation with increased end expiratory lung volume (EELV) and residual 
volume (RV). Corresponding reductions occur in inspiratory capacity (IC) and 
inspiratory reserve volume (IRV). Total lung capacity (TLC) is unchanged. As a 
result, tidal breathing becomes shifted rightward on the pressure-volume curve, 
closer to TLC. Mechanically, increased pressures must be generated to maintain 
tidal volume (VT). At EELV during exacerbation, intrapulmonary pressures do not 
return to zero, representing the development of intrinsic positive end expiratory 
pressure (PEEPi) which imposes increased inspiratory threshold loading (ITL) on 
the inspiratory muscles (inset); during the subsequent respiratory cycle, PEEPi 
must first be overcome in order to generate inspiratory flow.  
B. Representative flow-volume loops from a patient before and after onset of 
symptoms compatible with exacerbation. During exacerbation, there is evidence 
of worsening EFL (arrow) resulting in hyperinflation with an increased EELV and 
reduced IC (15).  
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Figure 3. A. Relationship between severity of exertional dyspnea and IC at the end of 6- 
minute walk distance (r = -0.49, P<0.00001). (88). 
B. Relationship of changes in visual analogue scale (VAS) measurement of 
dyspnea with placebo correction (%) with changes in IC 30 minutes after 
bronchodilation in patients with baseline IC <80% predicted (: salbutamol; 
: formoterol; : salmeterol; : oxitropium (r = 0.70, P<0.001) (89). 
 
Figure 4. Schematic representation of symptom improvement in an individual patient by 
 treatment interventions during the course of a single exacerbation: (A) a small 
reduction in the baseline threshold of symptoms accompanied by a similar 
magnitude of reduction of exacerbation symptoms; (B) reduction of exacerbation 
symptoms only; (C) a significant reduction of the threshold of baseline symptoms 
accompanied by a significant reduction of exacerbation symptoms. Solid lines 
represent the course of symptoms without intervention; dotted lines represent 
the course of symptoms after intervention. 
 
Figure 5.  A. Effects of the LAMA tiotropium, the LABA olodaterol, and their combination on 
neutrophil adhesion stimulated by sputum supernatants from patients with COPD.  
B. Expression of MAC-1 adhesion protein by neutrophils in induced sputum 
supernatants (99). 
*p<0.001 vs COPD; **p<0.0001 vs COPD; 
#
p<0.01 vs COPD; 
##
p<0.001 vs COPD 
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Figures 
Figure 1 
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Figure 2.   
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Figure 3. 
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Figure 4.  
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Figure 5.   
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